ACUT — ACCUSTEM SCIENCES Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AccuStem Sciences, Inc. is a clinical-stage diagnostics company. It is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. It focuses on its proprietary genomic tests, MicroRNA Signature Classifier (MSC) for patients with lung nodules and StemPrintER for patients with early-stage breast cancer. The MSC test, a 24-micro-RNA (miRNA) assay designed to help determine whether lung nodules identified by low-dose computer tomography (LDCT) screening, are benign or malignant. StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. The assay is developed to measure the stemness of tumors, or how much a tumor behaves like stem cells, which could indicate how likely a cancer is to recur or be resistant to standard treatments, ultimately impacting how patients are managed by their multidisciplinary care team.
Directors
- Wendy Blosser CEO (59)
- Joe Flanagan OTH (51)
- Keeren Shah CFO (49)
- Gabriele Cerrone DRC (53)
- Willy Simon IND (73)
- John Brancaccio IND (77)
- Sean McDonald IND (65)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 28th, 2021
- Public Since
- March 1st, 2022
- No. of Shareholders
- 497
- No. of Employees
- 4
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 16,072,267
- Address
- 5 Penn Plaza, 19th Floor, #1954, NEW YORK, 10001
- Web
- https://accustem.com/
- Phone
- +1 2070661000
- Auditors
- Mercurious & Associates LLP
Latest News for ACUT
Upcoming Events for ACUT
Q3 2026 Accustem Sciences Inc Earnings Release
Q4 2026 Accustem Sciences Inc Earnings Release
Similar to ACUT
Aamaxan Transport
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced BioMedical Technologies
Pink Sheets on Nasdaq
Aibotics
Pink Sheets on Nasdaq
FAQ
As of Today at 18:03 UTC, shares in ACCUSTEM SCIENCES are trading at $0.13. This share price information is delayed by 15 minutes.
Shares in ACCUSTEM SCIENCES last closed at $0.13 and the price had moved by -87% over the past 365 days. In terms of relative price strength the ACCUSTEM SCIENCES share price has underperformed the S&P500 Index by -88.21% over the past year.
There is no consensus recommendation for this security.
Find out moreACCUSTEM SCIENCES does not currently pay a dividend.
ACCUSTEM SCIENCES does not currently pay a dividend.
ACCUSTEM SCIENCES does not currently pay a dividend.
To buy shares in ACCUSTEM SCIENCES you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.13, shares in ACCUSTEM SCIENCES had a market capitalisation of $2.09m.
Here are the trading details for ACCUSTEM SCIENCES:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ACUT
Based on an overall assessment of its quality, value and momentum ACCUSTEM SCIENCES is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ACCUSTEM SCIENCES. Over the past six months, its share price has underperformed the S&P500 Index by -56.89%.
As of the last closing price of $0.13, shares in ACCUSTEM SCIENCES were trading -83.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The ACCUSTEM SCIENCES PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
ACCUSTEM SCIENCES' management team is headed by:
- Wendy Blosser - CEO
- Joe Flanagan - OTH
- Keeren Shah - CFO
- Gabriele Cerrone - DRC
- Willy Simon - IND
- John Brancaccio - IND
- Sean McDonald - IND